HRAS and cancer: The distribution of HRAS codon mutations varied by cancer type, with a higher prevalence of HRAS G13 mutations in HNSCC (42/112, 37.5%), squamous NSCLC (41/90, 45.6%), and melanoma (22/55, 40%) and a higher prevalence of Q61 mutations in non-squamous NSCLC (18/34, 52.9%) compared to other mutations (Figure 1A).